May 15, 2018 / 11:11 AM / 12 days ago

BRIEF-Eli Lilly Says Phase 3 Study For Patients With Chronic Cluster Headache Did Not Meet Its Primary Endpoint

May 15 (Reuters) - Eli Lilly and Co:

* ELI LILLY AND CO - PHASE 3 STUDY FOR PATIENTS WITH CHRONIC CLUSTER HEADACHE DID NOT MEET ITS PRIMARY ENDPOINT

* ELI LILLY AND CO - CONDUCTED SEPARATE PHASE 3 STUDY FOR PATIENTS WITH CHRONIC CLUSTER HEADACHE, WHICH REPRESENTS 10-15 PERCENT OF CLUSTER HEADACHE CASES

* ELI LILLY AND CO - OBSERVED SAFETY AND TOLERABILITY PROFILE CONSISTENT WITH PREVIOUS STUDIES THAT EVALUATED GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE

* LILLY’S GALCANEZUMAB MEETS PRIMARY ENDPOINT IN PHASE 3 STUDY EVALUATING GALCANEZUMAB FOR THE PREVENTION OF EPISODIC CLUSTER HEADACHE Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below